WEKO3
アイテム
High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy
https://doi.org/10.18999/nagjms.81.3.351
https://doi.org/10.18999/nagjms.81.3.351d6944cd8-fe95-44b8-b0e3-1de9bda36a0f
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
02_Kozai.pdf (192.1 kB)
|
.png)
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2019-09-04 | |||||
| タイトル | ||||||
| タイトル | High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy | |||||
| 言語 | en | |||||
| 著者 |
Kozai, Yuka
× Kozai, Yuka× Itoh, Yoshiyuki× Kawamura, Mariko× Nakahara, Rie× Ito, Junji× Okada, Tohru× Kikkawa, Fumitaka× Ikeda, Mitsuru× Naganawa, Shinji |
|||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| 権利 | ||||||
| 言語 | en | |||||
| 権利情報Resource | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
| 権利情報 | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | cervical uterine cancer | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | hysterectomy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | vaginal stump recurrence | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | radiotherapy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | brachytherapy | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | This study aimed to evaluate the treatment outcomes of patients who received high-dose-rate intracavitary brachytherapy (HDR-BT) using Iridium-192 with or without external beam radiotherapy as definitive treatment for recurrent cervical cancer after hysterectomy. Thirty-six patients with local recurrence after hysterectomy received radiotherapy including HDR-BT from 2005 to 2013. Overall survival, local control rate, and progression-free survival were estimated retrospectively via the Kaplan-Meier method. Late adverse events were also scored using the Common Terminology Criteria for Adverse Events (version 3.0). Median follow-up time was 38 (range, 7.4–101.3) months. The 3-year estimates of overall survival, local control rate, and progression-free survival were 100.0%, 82.8%, and 76.8%, respectively. Two patients (5.6%) had grade 2 lymphedema, but no other adverse events greater than grade 2 were reported. In conclusion, HDRBT was an effective treatment modality for patients with cervical cancer recurrence in the vaginal stump. | |||||
| 言語 | en | |||||
| 出版者 | ||||||
| 出版者 | Nagoya University Graduate School of Medicine, School of Medicine | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| ID登録 | ||||||
| ID登録 | 10.18999/nagjms.81.3.351 | |||||
| ID登録タイプ | JaLC | |||||
| 関連情報 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | URI | |||||
| 関連識別子 | http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/813.html | |||||
| ISSN（print） | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 0027-7622 | |||||
| ISSN（Online） | ||||||
| 収録物識別子タイプ | EISSN | |||||
| 収録物識別子 | 2186-3326 | |||||
| 書誌情報 |
en : Nagoya Journal of Medical Science 巻 81, 号 3, p. 351-358, 発行日 2019-08 |
|||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
